Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
US8198258B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 22, 2011 |
| Grant date | Jun 12, 2012 |
| Priority date | — |
| Expiry date | Apr 22, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/322
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.